Literature DB >> 22300741

Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Selin Carkaci1, Beatriz E Adrada, Eric Rohren, Wei Wei, Mohammad A Quraishi, Osama Mawlawi, Thomas A Buchholz, Wei Yang.   

Abstract

RATIONALE AND
OBJECTIVES: The aim of this study was to determine an optimum standardized uptake value (SUV) threshold for identifying regional nodal metastasis on 18F-fluorodeoxyglucose (FDG) positron emission tomographic (PET)/computed tomographic (CT) studies of patients with inflammatory breast cancer.
MATERIALS AND METHODS: A database search was performed of patients newly diagnosed with inflammatory breast cancer who underwent 18F-FDG PET/CT imaging at the time of diagnosis at a single institution between January 1, 2001, and September 30, 2009. Three radiologists blinded to the histopathology of the regional lymph nodes retrospectively analyzed all 18F-FDG PET/CT images by measuring the maximum SUV (SUVmax) in visually abnormal nodes. The accuracy of 18F-FDG PET/CT image interpretation was correlated with histopathology when available. Receiver-operating characteristic curve analysis was performed to assess the diagnostic performance of PET/CT imaging. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated using three different SUV cutoff values (2.0, 2.5, and 3.0).
RESULTS: A total of 888 regional nodal basins, including bilateral axillary, infraclavicular, internal mammary, and supraclavicular lymph nodes, were evaluated in 111 patients (mean age, 56 years). Of the 888 nodal basins, 625 (70%) were negative and 263 (30%) were positive for metastasis. Malignant lymph nodes had significantly higher SUVmax than benign lymph nodes (P < .0001). An SUVmax of 2.0 showed the highest overall sensitivity (89%) and specificity (99%) for the diagnosis of malignant disease.
CONCLUSIONS: SUVmax of regional lymph nodes on 18F-FDG PET/CT imaging may help differentiate benign and malignant lymph nodes in patients with inflammatory breast cancer. An SUV cutoff of 2 provided the best accuracy in identifying regional nodal metastasis in this patient population.
Copyright © 2012 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300741      PMCID: PMC4128395          DOI: 10.1016/j.acra.2012.01.001

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  38 in total

1.  Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.

Authors:  A Gil-Rendo; G Zornoza; M J García-Velloso; F M Regueira; C Beorlegui; M Cervera
Journal:  Br J Surg       Date:  2006-06       Impact factor: 6.939

2.  Responsible conduct of radiology research. Part V. The Health Insurance Portability and Accountability Act and research.

Authors:  Matthew S Johnson; Marcia N Gonzales; Shelley Bizila
Journal:  Radiology       Date:  2005-12       Impact factor: 11.105

3.  SUV: standard uptake or silly useless value?

Authors:  J W Keyes
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

4.  Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  N Avril; J Dose; F Jänicke; S Ziegler; W Römer; W Weber; M Herz; W Nathrath; H Graeff; M Schwaiger
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

5.  Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.

Authors:  F Crippa; R Agresti; E Seregni; M Greco; C Pascali; A Bogni; C Chiesa; V De Sanctis; V Delledonne; B Salvadori; M Leutner; E Bombardieri
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

6.  Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.

Authors:  L P Adler; P F Faulhaber; K C Schnur; N L Al-Kasi; R R Shenk
Journal:  Radiology       Date:  1997-05       Impact factor: 11.105

7.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

8.  18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma.

Authors:  Elisa Rush Port; Henry Yeung; Mithat Gonen; Laura Liberman; James Caravelli; Patrick Borgen; Steven Larson
Journal:  Ann Surg Oncol       Date:  2006-03-16       Impact factor: 5.344

9.  Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis.

Authors:  B Chevallier; B Asselain; A Kunlin; C Veyret; P Bastit; Y Graic
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

10.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program.

Authors:  P H Levine; S C Steinhorn; L G Ries; J L Aron
Journal:  J Natl Cancer Inst       Date:  1985-02       Impact factor: 13.506

View more
  2 in total

1.  Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.

Authors:  Ana María García Vicente; Angel Soriano Castrejón; Miguel Angel Cruz Mora; Ana González Ageitos; María del Mar Muñoz Sánchez; Alberto León Martín; Ruth Espinosa Aunión; Fernanda Relea Calatayud; Vicente Muñoz Madero; Ignacio Chacón López-Muñiz; Jose Manuel Cordero García; Germán Andrés Jiménez Londoño
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-28       Impact factor: 9.236

2.  Predictive Value of 18F-FDG PET/CT-Based Radiomics Model for Occult Axillary Lymph Node Metastasis in Clinically Node-Negative Breast Cancer.

Authors:  Kun Chen; Guotao Yin; Wengui Xu
Journal:  Diagnostics (Basel)       Date:  2022-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.